Singletto develops novel antimicrobial solutions and singlet oxygen technology to protect against pathogens.
Singletto has raised $10.0M in total funding. The most recent round was Series A. The last funding was announced in October 2025.
Singletto is headquartered in Seattle, United States.
Singletto develops novel antimicrobial solutions and singlet oxygen technology to protect against pathogens.
Singletto is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Singletto — Funding & Investors." VCBacked, October 9, 2025, https://www.vcbacked.co/company/singletto. Accessed August 1, 2026.
VCBacked. (2025). Singletto — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/singletto
{{cite web |title=Singletto — Funding & Investors |url=https://www.vcbacked.co/company/singletto |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated